XenoScreens: Using Clinically Relevant PDX Models for Translatable Results and Accelerated Decisions
- CDK4/6i Resistant, Breast Cancer
- KRAS G12X, Multi-Indication
- PIK3CA Hot Spot Mutations, Multi-Indication
- Post Clinical ADC Rx, Multi-Indication
- CCNE1/2 Amp, Multi-Indication
- Prostate Cancer, PCA/CRPC/NEPC
- FGFR1-4 Mutated, Multi-Indication
- EGFR/ALK Mutated, Multi-Indication
Fast-Track Your Preclinical Program with a Ready-to-Run PDX Mouse Trial
Accelerate development decisions with our mouse clinical trial (MCT) offerings—now open for enrollment. These turnkey PDX screens feature a diverse, well-characterized panel, complete with deep clinical annotation and robust biomarker data including IHC, WES and RNAseq profiles.
XenoScreen Study Design Specifics
-
Design: Group TGI endpoint, unlimited treatment arms with group sizes of n=1-3, pooled untreated control data of n=5 with purchase of single control per model
-
Initiation: Rolling enrollment, combination and staggered dosing regimens available
-
Duration: Defined endpoints with extensions possible
- Panel: Flexible with defined participation minimums
XenoScreen Deliverables
- Data: Body weights and tumor volumes collected twice weekly, biweekly updates
- Reporting: Final data with %T/C waterfall plots per treatment
- New Drug Data: Access to new XenoSTART sponsored efficacy data for contracted models, when applicable
- Samples: Flash frozen and FFPE block included from each purchased animal, when possible
Secure Your Competitive Edge—Enroll Today
Whether you’re testing single agents, combination therapies, or breakthrough mechanisms, our proven MCT platform delivers rapid, clinically relevant data to power IND submissions and inform critical go/no-go decisions. With limited slots and a set screen initiation timeline, now is the time to claim your spot and fast-track your drug development program.